Abstract
The addition of lapatinib (Tykerb/Tyverb) to capecitabine (Xeloda) delays disease progression more effectively than capecitabine monotherapy in women with previously treated HER2+ metastatic breast cancer (MBC). The quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TWiST) method was used to compare treatments. The area under survival curves was partitioned into health states: toxicity (TOX), time without symptoms of disease progression or toxicity (TWiST), and relapse period until death or end of follow-up (REL). Average times spent in each state, weighted by utility, were derived and comparisons of Q-TWiST between groups performed with varying combinations of the utility weights. Utility weights of 0.5 for both TOX and REL, that is, counting 2 days of TOX or REL as 1 day of TWiST, resulted in a 7-week difference in quality-adjusted survival favouring combination therapy (P=0.0013). The Q-TWiST difference is clinically meaningful and was statistically significant across an entire matrix of possible utility weights. Results were robust in sensitivity analyses. An analysis with utilities based on EQ-5D scores was consistent with the above findings. Combination therapy of lapatinib with capecitabine res...Continue Reading
References
Apr 15, 1991·Annals of Internal Medicine·R D GelberF Cavalli
Nov 1, 1990·Statistics in Medicine·P P GlasziouR D Gelber
Dec 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R D Gelber, A Goldhirsch
Nov 5, 1990·Health Policy·UNKNOWN EuroQol Group
Sep 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C C EarleP J Neumann
Aug 11, 2001·Lancet·B F ColeA Goldhirsch
Mar 12, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M A NooijUNKNOWN EORTC Breast Cancer Group
Mar 21, 2006·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Dennis A RevickiBernard F Cole
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Jan 12, 2008·Breast Cancer Research and Treatment·David CameronCharles E Geyer
Citations
Nov 21, 2012·BMC Medical Research Methodology·Milo A PuhanCynthia M Boyd
Sep 13, 2012·BMC Cancer·Connie L Erickson-MillerConrad Messam
Nov 26, 2010·Expert Opinion on Drug Safety·Robyn J MacFarlane, Karen A Gelmon
Jan 26, 2010·Current Medical Research and Opinion·Beth SherrillHenry L Gomez
Mar 11, 2010·Current Medical Research and Opinion·B KaufmanS Johnston
Sep 1, 2015·Health Technology Assessment : HTA·Jo PicotJackie Bryant
Aug 31, 2016·Expert Review of Pharmacoeconomics & Outcomes Research·Noman ParachaKatherine S MacGilchrist
Jun 17, 2010·PharmacoEconomics·Arthur S ZbrozekShreekant Parasuraman
Jul 15, 2015·Therapeutic Advances in Urology·Elisa ZanardiGiuseppe Procopio
Feb 7, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·Caitlyn T SolemMarc F Botteman
Oct 15, 2011·Pharmaceutical Statistics·George Quartey, Jixian Wang
Oct 2, 2009·Drugs·James E Frampton
Sep 18, 2010·European Journal of Haematology·John HornbergerMikael Löthgren
May 10, 2012·British Journal of Cancer·S PatilR J Motzer
May 26, 2011·British Journal of Cancer·J WangJ Wiezorek
May 7, 2014·Asia-Pacific Journal of Clinical Oncology·Nicholas WilckenRichard Bell
Jun 12, 2014·Psycho-oncology·Wendy R Tate, Grant H Skrepnek
Aug 28, 2010·The Oncologist·Beth SherrillStephen Johnston
Oct 14, 2011·Current Medical Research and Opinion·Beth SherrillStephen Johnston
May 6, 2015·British Journal of Clinical Pharmacology·Francesco BellantiOscar Della Pasqua
Mar 24, 2016·Cancer·Jennifer L BeaumontDavid Cella
May 21, 2011·Cancer·Patricia K Corey-LisleDennis A Revicki